Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
In renal cell carcinoma (RCC), single members of the Wnt/β-catenin signaling cascade were recently identified to contribute to cancer progression. However, the role of Wnt1, one of the key ligands in β-catenin regulation, is currently unknown in RCC. Therefore, alterations of the Wnt1/β-catenin axis in clear cell RCC (ccRCC) were examined with regard to clinicopathology, overall survival (OS) and cancer specific survival (CSS). Corresponding ccRCCs and benign renal tissue were analyzed in 278 patients for Wnt1 and β-catenin expression by immunohistochemistry in tissue microarrays. Expression scores, including intensity and percentage of stained cells, were compared between normal kidney and ccRCCs. Data was categorized according to mean expression scores and correlated to tumor and patients’ characteristics. Survival was analyzed according to the Kaplan-Meier and log-rank test. Univariable and multivariable Cox proportional hazard regression models were used to explore the independent prognostic value of Wnt1 and β-catenin. In ccRCCs, high Wnt1 was associated with increased tumor diameter, stage and vascular invasion (p ≤ 0.02). High membranous β-catenin was associated with advanced stage, vascular invasion and tumor necrosis (p ≤ 0.01). Higher diameter, stage, node involvement, grade, vascular invasion and sarcomatoid differentiation (p ≤ 0.01) were found in patients with high cytoplasmic β-catenin. Patients with a high cytoplasmic β-catenin had a significantly reduced OS (hazard ratio (HR) 1.75) and CSS (HR 2.26), which was not independently associated with OS and CSS after adjustment in the multivariable model. Increased ccRCC aggressiveness was reflected by an altered Wnt1/β-catenin signaling. Cytoplasmic β-catenin was identified as the most promising candidate associated with unfavorable clinicopathology and impaired survival. Nevertheless, the shift of membranous β-catenin to the cytoplasm with a subsequently increased nuclear expression, as shown for other malignancies, could not be demonstrated to be present in ccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As c-Myc and Cyclin D1 are key drivers of cell proliferation, this directly links the PPP1R18/ERK/Wnt/β-catenin axis to the proliferative phenotype of ccRCC [56–58].”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568 · cited 2×
“Here, elevated transcription of LEF/TCF-responsive target genes, such as c-myc or cyclin D1, promote deregulated cell differentiation and apoptosis [10,12].”
Nusse, R., & Varmus, H. E. (1982) · Cell · doi:10.1016/0092-8674(82)90409-3 · Cited by 1,863 · cited 1×
“The first discovered Wnt1 protein was identified as a virus-induced proto-oncogene in mouse mammary tumors in 1982 [20].”
BackgroundThe many faces and functions of β‐catenin
Valenta, T., Hausmann, G., & Basler, K. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.150 · Cited by 1,598
Secreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 1×
“Second, the loss of function of Wnt antagonist has been frequently reported to be associated with Wnt/β-catenin signal activation and RCC development [30–34].”
BackgroundInoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960 · cited 1×
“These mechanisms are particularly evident in colorectal and hepatocellular carcinomas, where frequent associations with gene mutations of the β-catenin regulator genes, adenomatous polyposis coli (APC) or AXIN, are found [13].”
BackgroundInterplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt Signaling
Heuberger, J., & Birchmeier, W. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002915 · Cited by 619 · cited 1×
“In addition, canonical Wnt/β-catenin signaling affects EMT by cadherin-mediated cell adhesion, which controls the expression of adhesion enzymes, mesenchymal genes and directly affects cell motility [26].”
BackgroundWNT-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor–Mediated Transcription
Chen, S., Guttridge, D. C., You, Z., Zhang, Z., Fribley, A., Mayo, M. W., Kitajewski, J., & Wang, C.-Y. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.1.87 · Cited by 394
Gumz, M. L., Zou, H., Kreinest, P. A., Childs, A. C., Belmonte, L. S., LeGrand, S. N., Wu, K. J., Luxon, B. A., Sinha, M., Parker, A. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0143 · Cited by 297 · cited 1×
“In particular, the loss of secreted-Frizzled related proteins (sFRP) leads to increased cytoplasmic β-catenin levels in RCC experiments [33,34].”
BackgroundChen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., & Rabbani, S. A. (2004) · Cancer · doi:10.1002/cncr.20518 · Cited by 283 · cited 1×
“The overexpression of Wnt1 was reported in various human cancers and is also suggested to be involved in ccRCC progression, as observed in Wnt ligand screening in RCC cancer samples [8,19].”
BackgroundInduction of Kidney Epithelial Morphogenesis by Cells Expressing Wnt-1
Herzlinger, D., Qiao, J., Cohen, D., Ramakrishna, N., & Brown, A. M. C. (1994) · Developmental Biology · doi:10.1006/dbio.1994.1360 · Cited by 157 · cited 1×
“In this context, the Wnt1 ligand, the first member of Wnt family proteins, does not only play a key role in the induction of kidney morphogenesis, but also seems to participate in renal tumorigenesis [16,17].”
BackgroundDahl, E., Wiesmann, F., Woenckhaus, M., Stoehr, R., Wild, P. J., Veeck, J., Knüchel, R., Klopocki, E., Sauter, G., Simon, R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210345 · Cited by 145 · cited 1×
“Second, the loss of function of Wnt antagonist has been frequently reported to be associated with Wnt/β-catenin signal activation and RCC development [30–34].”
BackgroundLocalization of the Human β-Catenin Gene (CTNNB1) to 3p21: A Region Implicated in Tumor Development
Kraus, C. S., Liehr, T., Hülsken, J., Behrens, J., Birchmeier, W., Grzeschik, K., & Ballhausen, W. G. (1994) · Genomics · doi:10.1006/geno.1994.1493 · Cited by 130 · cited 1×
“, Von Hippel-Lindau (VHL)-mutations in renal cancers [27,28].”
BackgroundHirata, H., Hinoda, Y., Nakajima, K., Kawamoto, K., Kikuno, N., Ueno, K., Yamamura, S., Zaman, M. S., Khatri, G., Chen, Y., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25507 · Cited by 121 · cited 1×
“This phenomenon was also reported for a third group of Wnt pathway antagonists, the Dickkopf 1–3 proteins [36–38].”
BackgroundHirata, H., Hinoda, Y., Nakajima, K., Kawamoto, K., Kikuno, N., Kawakami, K., Yamamura, S., Ueno, K., Majid, S., Saini, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0558 · Cited by 100 · cited 1×
“This phenomenon was also reported for a third group of Wnt pathway antagonists, the Dickkopf 1–3 proteins [36–38].”
BackgroundMsx2 Exerts Bone Anabolism via Canonical Wnt Signaling
Cheng, S.-L., Shao, J.-S., Cai, J., Sierra, O. L., & Towler, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800851200 · Cited by 89 · cited 1×
“blot analysis and the recombinant proteins, both antibodies demonstrated high specific protein detection in breast carcinoma used as positive control, as well as no immunoreactivity in negative controls, with the primary antibody omitted [41].”
BackgroundFunctional Significance of Wnt Inhibitory Factor-1 Gene in Kidney Cancer
Kawakami, K., Hirata, H., Yamamura, S., Kikuno, N., Saini, S., Majid, S., Tanaka, Y., Kawamoto, K., Enokida, H., Nakagawa, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2534 · Cited by 80 · cited 1×
“Furthermore, the downregulation of another Wnt-antagonist, the Wnt-inhibitory factor 1 (WIF-1), is frequently observed in RCC, while the restoration of WIF-1 suppresses tumor growth [35].”
BackgroundHIF-2α Enhances β-Catenin/TCF-Driven Transcription by Interacting with β-Catenin
Choi, H., Chun, Y.-S., Kim, T.-Y., & Park, J.-W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0505 · Cited by 79 · cited 1×
“Furthermore, the Wnt/β-catenin pathway is closely linked to other key signaling pathways in RCC, including the PI3K/AKT [14] or the hypoxia-inducible factor [15] regulation.”
BackgroundAltered modulation of WNT–β-catenin and PI3K/Akt pathways in IgA nephropathy
Cox, S. N., Sallustio, F., Serino, G., Pontrelli, P., Verrienti, R., Pesce, F., Torres, D. D., Ancona, N., Stifanelli, P. F., Zaza, G., et al. (2010) · Kidney International · doi:10.1038/ki.2010.138 · Cited by 78 · cited 1×
“Furthermore, the Wnt/β-catenin pathway is closely linked to other key signaling pathways in RCC, including the PI3K/AKT [14] or the hypoxia-inducible factor [15] regulation.”
BackgroundThe Wnt-dependent signaling pathways as target in oncology drug discovery
Janssens, N., Janicot, M., & Perera, T. (2006) · Investigational New Drugs · doi:10.1007/s10637-005-5199-4 · Cited by 73
Chronological expression of Wnt target genes Ccnd1, Myc, Cdkn1a, Tfrc, Plf1 and Ramp3
Röhrs, S., Kutzner, N., Vlad-Fiegen, A., Grünwald, T., Ziegler, S., & Müller, O. (2009) · Cell Biology International · doi:10.1016/j.cellbi.2009.01.016 · Cited by 72
WNT10A Plays an Oncogenic Role in Renal Cell Carcinoma by Activating WNT/β-catenin Pathway
Hsu, R.-J., Ho, J.-Y., Cha, T.-L., Yu, D.-S., Wu, C.-L., Huang, W.-P., Chu, P., Chen, Y.-H., Chen, J.-T., & Yu, C.-P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047649 · Cited by 70 · cited 2×
“The performed ligand screening identified Wnt1 as the second most expressed Wnt ligand type in RCC tissue samples, without reporting any further related clinical or survival data [8].”
BackgroundMizushima, T., Nakagawa, H., Kamberov, Y. G., Wilder, E. L., Klein, P. S., & Rustgi, A. K. (2002) · PubMed · Cited by 69
Wnt antagonist DICKKOPF‐3 (Dkk‐3) induces apoptosis in human renal cell carcinoma
Ueno, K., Hirata, H., Majid, S., Chen, Y., Zaman, M. S., Tabatabai, Z. L., Hinoda, Y., & Dahiya, R. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20729 · Cited by 61 · cited 1×
“This phenomenon was also reported for a third group of Wnt pathway antagonists, the Dickkopf 1–3 proteins [36–38].”
BackgroundKatoh, M. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.1.209 · Cited by 60 · cited 1×
“In this context, the Wnt1 ligand, the first member of Wnt family proteins, does not only play a key role in the induction of kidney morphogenesis, but also seems to participate in renal tumorigenesis [16,17].”
BackgroundBilim, V. N., Kawasaki, T., Katagiri, A., Wakatsuki, S., Takahashi, K., & Tomita, Y. (2000) · PubMed · Cited by 54
Thévenod, F., & Chakraborty, P. K. (2010) · Current Molecular Medicine · doi:10.2174/156652410791316986 · Cited by 53 · cited 2×
“Here, elevated transcription of LEF/TCF-responsive target genes, such as c-myc or cyclin D1, promote deregulated cell differentiation and apoptosis [10,12].”
Backgroundβ‐Catenin expression and mutational analysis in renal cell carcinomas
Kim, Y., Kang, Y. K., Kim, J. B., Han, S. A., Kim, K. I., & Paik, S. R. (2000) · Pathology International · doi:10.1046/j.1440-1827.2000.01111.x · Cited by 53 · cited 6×
“Although, mutations of β-catenin are relatively rare events in ccRCC, high cytoplasmic β-catenin protein levels were reported in ccRCC, which suggests that alternative mechanisms mediated via growth factors or hypoxia-induced (HIF) pathways might be responsible for an upregulated β-catenin [3,4,29].”
BackgroundInfluentialOncogenic Functions of Secreted Frizzled-Related Protein 2 in Human Renal Cancer
Yamamura, S., Kawakami, K., Hirata, H., Ueno, K., Saini, S., Majid, S., & Dahiya, R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0012 · Cited by 49 · cited 1×
“In particular, the loss of secreted-Frizzled related proteins (sFRP) leads to increased cytoplasmic β-catenin levels in RCC experiments [33,34].”
BackgroundAlteration of Frizzled Expression in Renal Cell Carcinoma
Janssens, N., Andries, L. J., Janicot, M., Perera, T., & Bakker, A. C. (2004) · Tumor Biology · doi:10.1159/000081098 · Cited by 49 · cited 1×
“Wnt proteins bind to a cell surface receptor complex, which consists of members of the frizzled receptor family and the low-density-lipoprotein receptor-related proteins, 5/6 [22].”
BackgroundMethylation-associated silencing of SFRP1 in renal cell carcinoma
Ogawa (1994) · Oncology Reports · doi:10.3892/or_00000138 · Cited by 43 · cited 1×
“Second, the loss of function of Wnt antagonist has been frequently reported to be associated with Wnt/β-catenin signal activation and RCC development [30–34].”
BackgroundSecond-line systemic therapy for the treatment of metastatic renal cell cancer
Kruck, S., Bedke, J., Kuczyk, M. A., & Merseburger, A. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.43 · Cited by 35 · cited 1×
“Therefore, there is the definitive need for the improvement of therapeutic concepts, since progressive disease will develop, due to the inevitable development of a multi-drug resistance in metastatic renal cell carcinoma (mRCC) patients [2].”
BackgroundSelf-citationKruck, S., Merseburger, A. S., Hennenlotter, J., Scharpf, M. O., Eyrich, C., Amend, B., Sievert, K., Stenzl, A., & Bedke, J. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10649.x · Cited by 31 · cited 1×
“0 mm; all patient probes were assembled as triplets (benign tissue 1 core, ccRCC tissue 2 cores), as previously described [40].”
MethodSelf-citationThe expression and prognostic value of alpha-, beta- and gamma-catenins in renal cell carcinoma.
Aaltomaa, S. H., Lipponen, P., Kärjä, V. J., Lundstedt, S., Lappi, J., & Kosma, V. (2004) · PubMed · Cited by 24
Wnt signaling pathway analysis in renal cell carcinoma in young patients
Bruder, E., Moch, H., Ehrlich, D., Leuschner, I., Harms, D., Argani, P., Briner, J., Graf, N. M., Selle, B., Rufle, A., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800957 · Cited by 22 · cited 1×
“However, no nuclear staining was observed in malignant and normal tissues in this series [6].”
BackgroundLian, X., Duan, X., Wu, X., Li, C.-D., Chen, S., Wang, S., Cai, Y., & Weng, Z. (2012) · Urology · doi:10.1016/j.urology.2012.02.024 · Cited by 17
Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma
Ronkainen, H., Kauppila, S., Hirvikoski, P. P., & Vaarala, M. H. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-2 · Cited by 16 · cited 1×
“In contrast, other investigators found positive nuclear β-catenin immunostaining in 44% of 152 RCC patients and associated nuclear immunoreactivity with lower Fuhrman grades [39].”
ResultLoss of Heterozygosity on the Short Arm of Chromosome 3 in Renal Cancer
Maestro, M. L., del Barco, V., Casla, M. T. S., Moreno, J., Adrover, E., Izquierdo, L. G., Zanna, I., Fernández, C., Redondo, E., Blanco, J., et al. (2000) · Oncology · doi:10.1159/000012149 · Cited by 16 · cited 1×
“, Von Hippel-Lindau (VHL)-mutations in renal cancers [27,28].”
BackgroundZeitlin, B. D., Ellis, L. M., & Nor, J. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2578 · Cited by 15 · cited 1×
“Although, mutations of β-catenin are relatively rare events in ccRCC, high cytoplasmic β-catenin protein levels were reported in ccRCC, which suggests that alternative mechanisms mediated via growth factors or hypoxia-induced (HIF) pathways might be responsible for an upregulated β-catenin [3,4,29].”
BackgroundExpression of beta-catenin in renal cell carcinoma.
Zang, T., Zhuang, L., Zhang, Z., Xin, D., & Guo, Y. (2001) · PubMed · Cited by 10
Research works printed but not linked: 1
- Aaltomaa, 2004, The expression and prognostic value of α-, β- and γ-catenins in renal cell carcinoma, Anticancer Res, 24, 2407
Cited by
Wnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“Some of these aberrations include upregulation of Wnt1 [249] and Wnt10a [250], as well as downregulation of Wnt5a [251] and Wnt7a [252].”
BackgroundInhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients
Fendler, A., Bauer, D., Busch, J., Jung, K., Wulf-Goldenberg, A., Kunz, S., Song, K., Myszczyszyn, A., Elezkurtaj, S., Erguen, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14700-7 · Cited by 189
Wnt Signaling in Kidney Development and Disease
Wang, Y., Zhou, C. J., & Liu, Y. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.019 · Cited by 158
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 147
Metadata
- Authors
- Kruck, S., Eyrich, C., Scharpf, M., Sievert, K.-D., Fend, F., Stenzl, A., & Bedke, J.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Bedke, Jens
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-05-24
- Volume
- 14
- Issue
- 6
- Pages
- 10944-10957
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3709711
- OpenAlex
- W2016373982
- Cited by
- 70
- References
- 42
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 2 · 2014: 3 · 2013: 2
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- clear cell renal cell carcinoma, Wnt1, β-catenin, Wnt/β-catenin signaling, prognostic factors, overall survival, cancer-specific survival, clinicopathological features, vascular invasion, sarcomatoid differentiation, nuclear beta-catenin expression
- MeSH terms
- Carcinoma, Renal Cell, Cell Membrane, Cytoplasm, Female, Humans, Immunohistochemistry, Kidney, Kidney Neoplasms, Male, Middle Aged, Prognosis, Multivariate Analysis, Proportional Hazards Models, Disease-Free Survival, Wnt1 Protein, beta Catenin, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.